In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT

Cancer Research

Volumn 69, Issue 12, 2009, Pages 5073-5081

  Moses, Sylvestor A ^a   Ali, M Ahad ^b   Zuohe, Song ^c   Du Cuny, Lei ^d   Li, Li Zhou ^b   Lemos, Robert ^d   Ihle, Nathan ^d   Skillman, A Geoffrey ^e   Zhang, Shuxing ^d   Mash, Eugene A ^b   Powis, Garth ^d   Meuillet, Emmanuelle J ^a,c  

^a University of Arizona   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e OpenEye Scientific Software Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DODECYL N (1,3,4 THIADIAZOL 2 YL)BENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; PLECKSTRIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT;

ANIMALS; BLOOD PROTEINS; CELL LINE, TUMOR; FEMALE; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

EID: 67449161813     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3839     Document Type: Article

References (39)

1. Rebecchi MJ, Scarlata S. Pleckstrin homology domains: a common fold with diverse functions. Annu Rev Biophys Biomol Struct 1998;27:503-528 (Pubitemid 28286023)
2. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
3. Workman P, Clarke PA, Guillard S, Raynaud FI. Drugging the PI3 kinome. Nat Biotechnol 2006;24:794-796 (Pubitemid 44086618)
4. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395 (Pubitemid 34214843)
5. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998;335:1-13. (Pubitemid 28477043)
6. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003;546:108-112 (Pubitemid 36782290)
7. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 1997;7:261-269 (Pubitemid 27176852)
8. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 2005;307:1098-1101
9. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998;273:32377-32379 (Pubitemid 28557606)
10. S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-75
11. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998;273:13150-13156 (Pubitemid 28246883)
12. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-1545 (Pubitemid 30183422)
13. Li Q. Recent progress in the discovery of Akt inhibitors as anticancer agents. Expert Opin Ther Pat 2007;17:1077-1130 (Pubitemid 47610954)
14. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927
15. Masure S, Haefner B, Wesselink JJ, et al. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur J Biochem 1999;265:353-360 (Pubitemid 29466045)
16. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-21532 (Pubitemid 129519688)
17. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-1365 (Pubitemid 36666005)
18. Yang ZZ, Tschopp O, Di-Poi N, et al. Dosage-dependent effects of Akt1/protein kinase Bα (PKBα) and Akt3/PKBγ on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol 2005;25:10407-10418 (Pubitemid 41681964)
19. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-4245 (Pubitemid 29190320)
20. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-7429 (Pubitemid 32995029)
21. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444 (Pubitemid 47123510)
22. Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 2007;13:5845-5856 (Pubitemid 350148501)
23. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689 (Pubitemid 19213607)
24. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-554 (Pubitemid 24058210)
25. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol Cancer Ther 2003;2:389-399
26. Meuillet EJ, Ihle N, Baker AF, et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004;14:513-527
27. Mahadevan D, Powis G, Mash EA, et al. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther 2008;7:2621-2632
28. Milburn CC, Deak M, Kelly SM, Price NC, Alessi DR, Van Aalten DM. Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J 2003;375:531-538
29. Thomas CC, Deak M, Alessi DR, van Aalten DM. High-resolution structure of the pleckstrin homology domain of protein kinase B/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 2002;12:1256-1262
30. Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. PDB 2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res 2004;32:W665-7. (Pubitemid 38997419)
31. Powell AA, LaRue JM, Batta AK, Martinez JD. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 2001;356:481-486 (Pubitemid 32532359)
32. Paine-Murrieta GD, Taylor CW, Curtis RA, et al. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 1997;40:209-214 (Pubitemid 27257733)
33. Kuntz ID, Chen K, Sharp KA, Kollman PA. The maximal affinity of ligands. Proc Natl Acad Sci U S A 1999;96:9997-10002. (Pubitemid 29422500)
34. Casamayor A, Morrice NA, Alessi DR. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 1999;342:287-292 (Pubitemid 29425348)
35. Warren GI, Andrews CW, Capelli AM, et al. A critical assessment of docking programs and scoring functions. Med Chem 2006;49:5912-5931 (Pubitemid 44484938)
36. Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther 2006;5:713-722
37. Hiromura M, Okada F, Obata T, et al. Inhibition of Akt kinase activity by a peptide spanning the βA strand of the proto-oncogene TCL1. J Biol Chem 2004;279:53407-53418 (Pubitemid 40051845)
38. Bednarczyk D, Mash EA, Aavula BR, Wright SH. NBDTMA: a novel fluorescent substrate of the peritubular organic cation transporter of renal proximal tubules. Pflugers Arch 2000;440:184-192 (Pubitemid 30265927)
39. Barnes KR, Blois J, Smith A, et al. Fate of a bioactive fluorescent wortmannin derivative in cells. Bioconjug Chem 2008;19:130-137 (Pubitemid 351213843)